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Background: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage
non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21,
miR223 and miR-221) as potential biomarkers in early-stage NSCLC.
Methods: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the
miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that
five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly
dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation
experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126
early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC)
curves were generated for the five miRNAs.
Results: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with
relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96];
miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83].
Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in
smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five
miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma
subgroups.
Conclusions: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and
miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and
optimizing improvement should be performed on larger sample to confirm our results.
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Lung cancer causes extremely high mortality of cancer
death worldwide, almost 85% of which are from non-small
cell lung cancer (NSCLC) [1,2]. It was estimated that
NSCLC may remain to be one of leading cause of deaths
in the next 50 years [3]. Early detection is the most effect-
ive way to relieve this threatening disease, since five-year
survival rate is ~80% in early stages (stage I/II) but drops
sharply to ~14% in advanced stages (stage III/IV) [1]. Un-
fortunately, still 75% of NSCLC cases are diagnosed in* Correspondence: qinggeng@med-research.biz
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unless otherwise stated.advanced stages due to the lack of effective early diagnos-
tic methods [3].
Currently, pathological diagnosis based on biopsies re-
mains to be the standard methods for early-stage NSCLC
detection, such as bronchoscopy, which have an advantage
over the other methods since it can dynamically monitor
the aberrant conditions of lung, however, the invasive na-
ture of this technique poses a potential risk on human
body [4,5]. Imaging techniques, such as chest X-ray and
computed tomography (CT), are also used to detect early-
stage NSCLC [6-9], but the exposure to the radiation may
do harm to health. Considering these limitations of the ex-
pensive methods mentioned above, scientists turn to seek
noninvasive screening markers for early-stage NSCLCtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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noninvasive and cost-effective diagnostic tools for early-
stage NSCLC, such as CA-125, CA19-9, CEA, CYFRA21-
1, chromogranin A, NSE and TPS [10,11]. However, the
limited sensitivity and specificity hampered their further
application and development. Therefore, it is significantly
urgent to develop novel noninvasive biomarkers with high
accuracy for the screening of early-stage NSCLC.
Recently, a new group of RNA regulatory genes, micro-
RNAs (miRNAs), has been discovered to be closely associ-
ated with various human cancers, including NSCLC [12].
MiRNAs regulate post-transcriptionally the expression of
a wide range of genes, which play an important role in
controlling cell proliferation, differentiation, and apoptosis
[13-15]. Besides, accumulating studies have proven that
miRNAs can serve as tumor suppressors due to its dysreg-
ulated expression in cancer development and progression
by inhibiting the translation of 3′-untranslated region of
messenger RNAs [15]. As tumor-related genes, miRNAs
are considered to have the potential diagnostic value in
the cancer detection. Furthermore, miRNAs as cancer bio-
markers show additional advantages: (1) miRNAs are easy
to extract since they universally exist in tissue or body
fluids, such as serum, plasma, urine, etc.; (2) miRNAs
show strong stability and resistance to boiling, extended
storage, RNase degradation, extremes of PH, and multiple
freeze-thaw cycles [16]. Based on the above evidences, it is
obvious that miRNAs have great potential as noninvasive
and easy-operating methods in the cancer detection.
Over the past few years, several studies have indicated
that some miRNAs can serve as potential biomarkers for
NSCLC with high accuracy, as its expression levels be-
tween NSCLC patients and healthy controls show signifi-
cant differences [11,17-19]. However, there are few studies
focusing on the potential predictive value of miRNAs for
early-stage NSCLC. As we know, early detection is the
most effective way to reduce the high mortality of NSCLC,
and we carried out this study to investigate potential miR-
NAs for early-stage NSCLC diagnosis. In this study, we se-
lected 12 candidate plasma miRNAs mentioned in these
studies [11,17-21], which are claimed to have predictive
value in early-stage NSCLC, including miR-30d, miR-383,
miR-20a, miR-145, miR-221, miR-25, miR-223, miR-21,
miR-126, miR-155, miR-182, and miR-210. We first inves-
tigated the expression levels of miRNAs in plasma for
early-stage NSCLC using real-time quantitative reverse
transcription PCR (real-time qRT-PCR). And then we
picked out five miRNAs (miR-20a, miR-145, miR-21,
miR223 and miR-221) which showed significant differ-
ences in the expression levels between cancer patients and
controls to perform further investigation to confirm their
diagnostic value. The application of these plasma miRNAs
as biomarkers for early-stage NSCLC screening will be
interpreted in this study.Methods and materials
Selection of plasma miRNAs
According to a large number of relevant articles which
have reported the diagnostic value of miRNAs for NSCLC
[11,17-21], we chose 12 miRNAs as our research target,
including miR-30d, miR-383, miR-20a, miR-145, miR-221,
miR-25, miR-223, miR-21, miR-126, miR-155, miR-182,
and miR-210. The inclusion criteria can be summarized as
follows: (1) they have been proven to exist in plasma; (2)
The expression levels of these miRNAs showed significant
differences in between NSCLC patients and healthy con-
trols; (3) they suggest potential diagnostic value in early
stage NSCLC detection.
Ethic statement and patient samples
In this double-blind experiment, all the subjects were
selected from Renmin Hospital of Wuhan University
(Wuhan, China) and we have obtained informed consents
from all of the participants with the approval from the eth-
ics committee of Renmin Hospital of Wuhan University.
In total, 151 early stage NSCLC patients were recruited.
Gold standard methods, including lung biopsy specimens
and imaging techniques, were applied to confirm the
histopathological features and tumor stages of NSCLC pa-
tients. None of the patients have ever received surgery or
chemotherapy before. 85 healthy controls were selected
including smokers and non-smokers but with no history
of pulmonary diseases. 42 non-cancerous pulmonary dis-
ease (NCPD) patients were further recruited as a control
group, including 25 chronic obstructive pulmonary disease
(COPD) patients and 17 benign pulmonary nodule (BPN)
patients. All the necessary information of patients and
healthy controls is provided in Table 1.
Study design: training set and validation set
This study was divided into two sets, training set and val-
idation set. In the training set, we chose 25 early-stage
NSCLC patients and 25 age- and gender-matched healthy
controls to compare the expression profile of these 12
miRNAs between NSCLC patients and healthy controls.
There are no significant differences in age, gender and
smoking status. According to the training set results, we
then find some of the miRNAs that show statistically sig-
nificant differences in expression levels, and performed a
validation experiment to further investigate the diagnostic
proficiency of these miRNAs. In the validation set, plasma
samples were drawn from all participants complying with
the World Health Organization (WHO) categories, in-
cluding 126 early-stage NSCLC patients, 42 NCPD pa-
tients and 60 healthy controls.
RNA isolation and qRT-PCR analysis for miRNAs
Blood samples (5 mL per subjects) were drawn and
stored into BD Vacutainer spray-coated K2EDTA Tubes
Table 1 Demographic and clinical characteristics of early-stage NSCLC patients and healthy controls
Training set Validation set
NSCLC (n = 25) Healthy (n = 25) P-value NSCLC (n = 126) NCPD (n = 42) Healthy (n = 60) P-value
Age
≤60 14 13 0.777 79 26 35 0.847
>60 11 12 47 16 25
Sex
Male 15 12 0.395 87 29 36 0.443
Female 10 13 39 13 24
Smoking status
Current 9 7 0.807 54 21 17 0.004
Former 13 14 35 13 11
Never 3 4 37 8 32
TNM stage
Stage I 9 - - 54 - - -
Stage II 16 - 72 - -
Histological type
Adenocarcinoma 8 - - 45 - - -
Squamous carcinoma 13 - 64 - -
Others 4 - 17 - -
NSCLC, non-small cell lung cancer; NCPD, non-cancerous pulmonary disease.
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each blood sample was centrifuged at 2,000 × g for
10 min at 4°C aiming at isolating the plasma from blood,
which was then immediately transferred into a new
Eppendorf tube and frozen to −80°C until RNA extrac-
tion process. In all 50 μL RNA was isolated from each
500 μL plasma sample.
After solution, 20 μL reactions including miRNA-
specific reverse primers and transcription (RT) mixtureTable 2 Expression levels of 12 plasma miRNAs between
early-stage NSCLC patients and healthy controls
miRNAs Expression NSCLC/Healthy P value
miR-20a ↑ 12.34 ± 0.78 1.45 × 10−3
miR-223 ↑ 5.67 ± 0.56 2.34 × 10−3
miR-21 ↑ 5.09 ± 0.53 3.31 × 10−5
miR-155 ↑ 4.34 ± 0.3 1.67 × 10−3
miR-221 ↑ 1.32 ± 0.29 0.063
miR-25 ↑ 1.26 ± 0.28 0.082
miR-182 ↑ 1.03 ± 0.27 0.723
miR-30d ↑ 0.98 ± 0.25 0.459
miR-126 ↑ 0.87 ± 0.24 0.239
miR-320 ↑ 1.84 ± 0.77 0.071
miR-210 ↑ 0.57 ± 0.15 0.563
miR-145 ↑ 20.24 ± 0.83 3.56 × 10−4were added to plasma RNA to initiate the transcription of
these 12 miRNAs. These procedures were performed on
miScript SYBR Green PCR kit (Qiagen, Germany) with
abidance by the manufacturer’s protocol. Quantitative
PCR was carried out on a Bio-Red IQ5 Multi-color RT-
PCR Detection System (Bio-Red, Hercules, CA, USA).
Comparative cycle threshold (Ct) was calculated to define
the expression level of these miRNAs. MiR-16 was se-
lected as internal reference, since accumulating studies
have reported that it is relatively stable in the test envi-
ronment [22-25]. The expression level of each included
miRNA can be determined by this equation: 2-△△Ct, ΔCt =
Ct (reference miR-16) - Ct (miRNA). Each qRT-PCR test
was conducted in triplicate. Besides, in order to rule out
the effects from test environment, one no-template con-
trol and two interpolate controls were performed alone
for each sample.
Statistics analysis
The significances of 12 included miRNAs were appraised
by Mann–Whitney test. In the training set, the expression
levels of these 12 miRNAs in between patients and healthy
controls were detected individually, with a P value less
than 0.05 showing no significant diagnostic value in differ-
entiating the early-stage NSCLC patients from healthy
controls. After selecting those effective miRNAs, we fur-
ther conducted experiment based on each miRNA. Except
for the same tests mentioned above which should be
Figure 1 Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-20a.
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prehensively evaluate the diagnostic value of these miR-
NAs as biomarkers for early-stage NSCLC detection.
Thus, receiver operating characteristic (ROC) curve was
established to interpret the ability of miRNA in discri-
minating patients from healthy controls. The area under
the curve (AUC), sensitivity and specificity at the optimal
cutoff were computed, which would validate the diagnos-
tic application of these effective miRNAs as cancer bio-
markers. All the P values were bilaterally shown, with a
value less than 0.05 indicating statistically significance.
Results
Demographic and clinicopathological characteristics of
subjects
Of the 25 NSCLC patients in the training set, 9 patients
are at stage I and 16 at stage II; 8 are suffered from adeno-
carcinoma, 13 with squamous carcinoma and 4 with other
subtype NSCLC. A total of 25 healthy controls were se-
lected for training set. The age, sex and smoking habit of
healthy controls were well matched with NSCLC patients.
In the validation set, there were in total 126 NSLCL
patients, 42 NCPD patients and 60 healthy controls. Al-
though the case and control groups were well matched forFigure 2 Scatter plot of expression levels (a) and Receiver operator cage (P = 0.847) and sex (P = 0.443) as shown in revised
Table 1, smoking habit (P = 0.004) as an uncontrollable
variable was not matched well between NSCLC patients
and controls. Therefore, we conducted further stratified
analysis according to smoking habit, which classified both
NSCLC patients and controls into two groups, such as
smokers (former and current smokers) and non-smokers.
These demographic and clinicopathological characteristics
for subjects were listed in Table 1 in details.Evaluation of 12 candidate miRNAs as biomarkers for
NSCLC screening in training set
In the training set, we tested 12 candidate miRNAs in
plasma samples by qRT-PCR in both cases and controls.
The relative expression of 12 miRNAs was measured in
plasma RNA for 25 NSCLC patients and 25 healthy con-
trols, as shown in Table 2. We found that all miRNAs ex-
hibited an up-regulated trend in NSCLC patients, but only
five miRNAs (miR-20a, miR-223, miR-21, miR-221 and
miR-145) showed significant differences between NSCLC
patients and healthy controls. Hence, these five miRNAs
were further investigated in a large-scale sample in valid-
ation set in order to validate their diagnostic accuracy.haracteristic (ROC) curve (b) analysis of plasma miR-223.
Figure 3 Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-21.
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screening in validation set
In validation set, we choose these five miRNAs (miR-
20a, miR-223, miR-21, miR-221 and miR-145) as novel
biomarkers for NSCLC screening based on 126 NSCLC
patients, 42 NCPD patients and 60 healthy controls. We
first pondered the predictive application of these five
miRNAs by comparing the relative expression in plasma
between NSCLC patients and two control groups. As
shown in Figures 1, 2, 3, 4 and 5, there were different
expression of these five miRNAs between NSCLC pa-
tients and healthy controls (all P < 0.001), as well as
NSCLC patients and NCPD controls. However, no sig-
nificant difference was observed between NCPD patients
and healthy controls for miR-20a, miR-21, miR-221 and
miR-145 (all P > 0.05), except for miR-223 (P < 0.01).
ROC curve analyses were conducted to figure out the
sensitivity and specificity of these five miRNAs as bio-
markers in the screening of NSCLC (Table 3). For the
training set, the AUC of each ROC curve of these 5 miR-
NAs ranged from 0.79 to 0.96, as follows: miR-20a, 0.91
with 95% confidence interval (CI) of [0.86-0.95]; miR-
223, 0.96 with 95% CI of [0.94-0.98]; miR-21, 0.79 with
95% CI of [0.73-0.86]; miR-155, 0.94 with 95% CI of
[0.91-0.97]; miR-145, 0.82 with 95% CI of [0.75-0.88].Figure 4 Scatter plot of expression levels (a) and Receiver operator cFor the validation set, similar results were obtained, as
follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-
223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with
95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of
[0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83].
Furthermore, we conducted stratified analyses in differ-
ent clinical-pathological subgroups, according to smoking
habit (smoker vs. non-smoker), tumor stage (stage I-II vs.
stage III-IV), and histological type (adenocarcinoma vs.
squamous carcinoma), as shown in Table 4. Our results
indicated that miR-20a, miR-223, miR-21 and miR-145
showed better diagnostic performance in smokers than in
non-smokers, while miR-155 might be more suitable for
non-smokers. In addition, all of these five miRNAs could
differentiate NSCLC from controls with a higher accuracy
in advanced stage and squamous carcinoma subgroups.
Discussion
Although NSCLC has high mortality rate among can-
cers, the NSCLC patients are more likely to survive if
they are diagnosed and received treatment at its early
stage, since the five-year survival rate of early-stage can-
cer can reach up to 80%. Current diagnostic methods for
NSCLC mainly consist of pathological biopsy, imaging
diagnosis and protein biomarkers, which however, sufferharacteristic (ROC) curve (b) analysis of plasma miR-155.
Figure 5 Scatter plot of expression levels (a) and Receiver operator characteristic (ROC) curve (b) analysis of plasma miR-145.
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miRNAs would open a door to the promising perspec-
tive of accurate early diagnosis of NSCLC as they are
noninvasive tumor-specific biomarkers to discriminate
patients from healthy controls with high sensitivity and
specificity.
Over the past few years, scientists have found sufficient
evidences to confirm the aberrant expression of miRNAs
between cancer patients and healthy people which have a
strong correlation with cancer development [26,27]. Chen
et al. found a significant difference in the expression levels
of serum miRNAs between NSCLC patients and healthy
controls [11]. Tang et al. revealed that miRs-21, 145 and
−155 can serve as noninvasive screening tool in the early
detection of lung cancer with relatively high accuracy [21].
Subsequently, increasing studies have investigated the
diagnostic value of miRNAs for early-stage lung cancer.
Compared with these previous studies, our present study
has several advantages. Firstly, we concentrated on the de-
tection of early-stage NSCLC by using miRNAs as bio-
markers, which was a novel research field aiming at
reducing the high mortality through early detection. Sec-
ondly, 12 miRNAs were included in our research and 5
miRNAs were confirmed to have diagnostic value, thus
expanding the investigation number of miRNAs, which
would make the interpretation more comprehensively and
systematically.
Our results suggested that NSCLC patients and the
healthy people have the aberrant expression levels ofTable 3 Sensitivity and specificity and AUC of 5 identified mi
MiRNA Training set (NSCLC vs. Healthy)
Sensitivity (95% CI) Specificity (95% CI) AUC (95% C
miR-20a 0.84 [0.76-0.90] 0.83 [0.71-0.92] 0.91 [0.86-0.9
miR-223 0.87 [0.80-0.93] 0.86 [0.75-0.94] 0.96 [0.94-0.9
miR-21 0.70 [0.61-0.78] 0.68 [0.55-0.80] 0.79 [0.73-0.8
miR-155 0.87 [0.80-0.93] 0.87 [0.75-0.94] 0.94 [0.91-0.9
miR-145 0.73 [0.64-0.81] 0.75 [0.62-0.85] 0.82 [0.75-0.8these five plasma miRNAs (miR-20a, miR-223, miR-21,
miR-221 and miR-145). The data from our study demon-
strated that the each single miRNA present high sensitivity
and specificity in the detection process. Despite of differ-
ent expression levels, all of these five miRNAs were vali-
dated to have potential to discriminate the early-stage
NSCLC patients from healthy controls. However, qRT-
PCR analyses suggested that there was no significant ex-
pression difference between NCPD patients and healthy
controls for all five miRNA. During the research, we found
that the functional pattern and expression level of these
miRNAs can lead to the pathological alterations, due to
their underlying functions tumor suppressors or onco-
genes, which makes them effective indicators in cancer
diagnosis [28-31].
Among these five miRNAs, miR-20a, −223 and miR-
155 were demonstrated as the most sensitive and spe-
cific biomarkers in the detection of NSCLC, showing the
superior accuracy. Previous findings have confirmed that
miR-20a can inhibit E2F1 directly, which is a transcrip-
tion factor associated with the lung cancer cell growth
[32], thus making miR-20a helpful for the early diagnosis
of NSCLC. As for miR-155, scientists have proven that
restoration of miR-155 represses the growth of NSCLC
malignant cells in the epidermal growth factor receptor
mutant, which can serve as reasonable explanation for
miR-155 as a NSCLC biomarker at present [33,34].
In our study, we have demonstrated these five miRNAs
in plasma showed dysregulated expression in NSCLC,RNAs in detecting early-stage NSCLC
Validation set (NSCLC vs. Control)
I) Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
5] 0.83 [0.74-0.89] 0.81 [0.72-0.88] 0.89 [0.85-0.93]
8] 0.87 [0.80-0.92] 0.86 [0.78-0.92] 0.94 [0.91-0.96]
6] 0.67 [0.54-0.72] 0.68 [0.59-0.77] 0.77 [0.71-0.83]
7] 0.86 [0.78-0.91] 0.84 [0.76-0.91] 0.92 [0.89-0.96]
8] 0.70 [0.61-0.78] 0.68 [0.58-0.76] 0.77 [0.71-0.83]
Table 4 Subgroup analysis of predictive value for the 5 identified miRNAs in validation set
MiRNAs NSCLC vs. Healthy NSCLC vs. NCPD NCPD vs. Healthy
SEN SPE AUC SEN SPE AUC SEN SPE AUC
miR-20a 0.81 0.85 0.91 0.81 0.81 0.86 0.60 0.63 0.61
Smokers 0.89 0.89 0.98 0.85 0.85 0.94 0.64 0.52 0.61
Non-smokers 0.63 0.63 0.64 0.70 0.73 0.75 0.66 0.67 0.68
Stage I 0.77 0.76 0.84 0.76 0.76 0.77 0.63 0.59 0.61
Stage II 0.98 0.98 0.99 0.98 0.97 0.99 0.60 0.59 0.61
AC 0.87 0.83 0.90 0.84 0.81 0.85 0.61 0.59 0.62
SC 0.97 0.97 0.98 0.92 0.90 0.98 0.63 0.59 0.60
miR-223
Smokers 0.85 0.85 0.94 0.93 0.90 0.98 0.65 0.65 0.69
Non-smokers 0.78 0.78 0.93 0.78 0.75 0.89 0.72 0.75 0.73
Stage I 0.72 0.70 0.86 0.65 0.64 0.70 0.65 0.64 0.67
Stage II 0.97 0.97 0.98 0.94 0.95 0.98 0.65 0.64 0.67
AC 0.80 0.82 0.91 0.73 0.71 0.77 0.65 0.62 0.67
SC 0.95 0.93 0.98 0.92 0.93 0.98 0.65 0.64 0.67
miR-21
Smokers 0.83 0.81 0.87 0.78 0.75 0.84 0.63 0.63 0.64
Non-smokers 0.55 0.50 0.57 0.53 0.52 0.55 0.57 0.58 0.59
Stage I 0.67 0.67 0.69 0.57 0.57 0.61 0.56 0.57 0.58
Stage II 0.87 0.88 0.96 0.88 0.88 0.95 0.57 0.56 0.58
AC 0.60 0.60 0.63 0.51 0.50 0.56 0.57 0.57 0.58
SC 0.91 0.90 0.97 0.92 0.90 0.97 0.56 0.57 0.58
miR-155
Smokers 0.86 0.82 0.88 0.78 0.76 0.88 0.52 0.51 0.53
Non-smokers 0.91 0.93 0.98 0.89 0.88 0.98 0.65 0.63 0.64
Stage I 0.80 0.80 0.91 0.76 0.76 0.84 0.55 0.52 0.59
Stage II 0.94 0.95 0.97 0.83 0.83 0.95 0.55 0.52 0.60
AC 0.87 0.87 0.93 0.80 0.78 0.86 0.55 0.52 0.59
SC 0.92 0.90 0.96 0.81 0.81 0.93 0.52 0.52 0.59
miR-145
Smokers 0.96 0.96 0.98 0.95 0.90 0.97 0.57 0.58 0.68
Non-smokers 0.81 0.84 0.90 0.63 0.62 0.79 0.60 0.62 0.63
Stage I 0.59 0.57 0.62 0.51 0.50 0.55 0.52 0.52 0.58
Stage II 0.91 0.90 0.96 0.76 0.73 0.87 0.52 0.52 0.58
AC 0.71 0.70 0.77 0.57 0.55 0.59 0.55 0.50 0.58
SC 0.95 0.95 0.97 0.79 0.79 0.89 0.52 0.52 0.58
AC, adenocarcinoma; SC, squamous carcinoma.
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diagnosis of early-stage NSCLC. However, some limitations
in our tests needed to be noticed. Firstly, in order to acquire
a better and deeper understanding of the diagnostic per-
formance of these five miRNAs in the early detection of
NSCLC, more complementary researches on the regulatory
mechanism of miRNA in cancer should be needed to
confirm our results. Secondly, the combination of thesemiRNAs should be performed to find out the most effective
biomarker group and improve the diagnostic accuracy,
since the combination of miRNAs as screening tools may
be more sensitive and specific than single miRNA [18,21].
Besides, a larger sample size will be required to produce a
more convincing result in future. Ignoring these limitations,
our study still demonstrated authorized clinical diagnostic
methods for early-stage NSCLC.
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To sum up, sufficient evidences have been provided in
our study to show the aberrant expression in the levels
of plasma miR-20a, miR-223, miR-21, miR-221 and
miR-145 in early-stage NSCLC patients. The clinical
diagnostic value of each miRNA has been further evalu-
ated, which indicated that these five miRNAs can serve
as noninvasive biomarkers in the detection of early-
stage NSCLC individually. Nevertheless, further valid-
ation study should be performed on larger sample to
confirm our results.
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